NASDAQ:ERNA Ernexa Therapeutics (ERNA) Stock Price, News & Analysis $8.15 +0.15 (+1.88%) As of 01:16 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Ernexa Therapeutics Stock (NASDAQ:ERNA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Ernexa Therapeutics alerts:Sign Up Key Stats Today's Range$8.03▼$8.8550-Day Range$3.69▼$13.6352-Week Range$3.18▼$75.00Volume24,444 shsAverage Volume1.00 million shsMarket Capitalization$9.50 millionP/E RatioN/ADividend YieldN/APrice Target$30.00Consensus RatingHold Company Overview Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts. Read More Ernexa Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreERNA MarketRank™: Ernexa Therapeutics scored higher than 46% of companies evaluated by MarketBeat, and ranked 641st out of 868 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingErnexa Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialErnexa Therapeutics has a consensus price target of $30.00, representing about 252.9% upside from its current price of $8.50.Amount of Analyst CoverageErnexa Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Ernexa Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Ernexa Therapeutics are expected to grow in the coming year, from ($18.02) to ($1.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ernexa Therapeutics is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ernexa Therapeutics is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioErnexa Therapeutics has a P/B Ratio of 1.11. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Ernexa Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.02% of the float of Ernexa Therapeutics has been sold short.Short Interest Ratio / Days to CoverErnexa Therapeutics has a short interest ratio ("days to cover") of 0.02, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ernexa Therapeutics has recently increased by 21.73%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldErnexa Therapeutics does not currently pay a dividend.Dividend GrowthErnexa Therapeutics does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment-0.54 News SentimentErnexa Therapeutics has a news sentiment score of -0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Ernexa Therapeutics this week, compared to 2 articles on an average week.Search Interest10 people have searched for ERNA on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Ernexa Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Ernexa Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders0.53% of the stock of Ernexa Therapeutics is held by insiders.Percentage Held by Institutions70.55% of the stock of Ernexa Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ernexa Therapeutics' insider trading history. Receive ERNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ernexa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ERNA Stock News HeadlinesBrookline Capital Markets Forecasts ERNA Q2 EarningsJune 1 at 1:02 AM | americanbankingnews.comErnexa Therapeutics (NASDAQ:ERNA) Rating Lowered to Sell at Wall Street ZenMay 30, 2026 | americanbankingnews.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.June 3 at 1:00 AM | Profits Run (Ad)Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical DevelopmentMay 27, 2026 | globenewswire.comErnexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 OpportunityMay 20, 2026 | globenewswire.comERNA stock almost doubled in value today – smashing rally leads to 7 trading haltsMay 14, 2026 | msn.comErnexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101May 11, 2026 | globenewswire.comErnexa Therapeutics Inc.: Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer ModelsMay 7, 2026 | finanznachrichten.deSee More Headlines ERNA Stock Analysis - Frequently Asked Questions How have ERNA shares performed this year? Ernexa Therapeutics' stock was trading at $30.00 at the start of the year. Since then, ERNA stock has decreased by 71.7% and is now trading at $8.50. How were Ernexa Therapeutics' earnings last quarter? Ernexa Therapeutics Inc. (NASDAQ:ERNA) released its earnings results on Monday, May, 11th. The company reported ($6.95) earnings per share for the quarter, missing the consensus estimate of ($1.95) by $5.00. When did Ernexa Therapeutics' stock split? Ernexa Therapeutics's stock reverse split on Monday, May 4th 2026.The 1-25 reverse split was announced on Thursday, April 30th 2026. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 1st 2026. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of Ernexa Therapeutics? Shares of ERNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ernexa Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ernexa Therapeutics investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), NIO (NIO), Bakkt (BKKT) and Company Calendar Last Earnings5/11/2026Today6/03/2026Next Earnings (Estimated)8/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3w+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 For the last 3 weeks, ERNA's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ERNA CIK748592 Webwww.brooklynitx.com Phone(212) 582-1199Fax760-438-3505Employees10Year Founded1953Price Target and Rating Average Price Target for Ernexa Therapeutics$30.00 High Price Target$30.00 Low Price Target$30.00 Potential Upside/Downside+267.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($26.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$14.08 million Net MarginsN/A Pretax Margin-1,831,114.25% Return on Equity-263.74% Return on Assets-151.16% Debt Debt-to-Equity RatioN/A Current Ratio2.89 Quick Ratio2.89 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.64 per share Price / Book1.07Miscellaneous Outstanding Shares1,166,000Free Float1,160,000Market Cap$9.51 million OptionableNo Data Beta2.49 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:ERNA) was last updated on 6/3/2026 by MarketBeat.com Staff. From Our PartnersThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredJune 12: $100 Turns Into $100,000?The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...Brownstone Research | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ernexa Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ernexa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
